Inventiva S.A. (EPA: IVA)
France
· Delayed Price · Currency is EUR 1.458
+0.008 (0.55%)
Oct 10, 2024, 9:41 AM CET
Inventiva Revenue
Inventiva had revenue of 2.73M EUR in the half year ending June 30, 2024, a decrease of -19.40%. This brings the company's revenue in the last twelve months to 19.28M, down -12.56% year-over-year. In the year 2023, Inventiva had annual revenue of 23.16M with 23.12% growth.
Revenue (ttm)
19.28M
Revenue Growth
-12.56%
P/S Ratio
3.83
Revenue / Employee
157.99K
Employees
123
Market Cap
76.87M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2023 | 23.16M | 4.35M | 23.12% |
| Dec 31, 2022 | 18.81M | 10.31M | 121.32% |
| Dec 31, 2021 | 8.50M | 3.24M | 61.52% |
| Dec 31, 2020 | 5.26M | -6.03M | -53.39% |
| Dec 31, 2019 | 11.29M | 3.91M | 53.02% |
| Dec 31, 2018 | Pro | Pro | Pro |
| Dec 31, 2017 | Pro | Pro | Pro |
| Dec 31, 2016 | Pro | Pro | Pro |
| Dec 31, 2015 | Pro | Pro | Pro |
| Dec 31, 2014 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Sanofi | 47.08B |
| EssilorLuxottica Société anonyme | 25.83B |
| Sartorius Stedim Biotech S.A. | 2.75B |
| bioMérieux S.A. | 3.81B |
| Eurofins Scientific SE | 6.72B |
| Ipsen S.A. | 3.44B |
| Virbac SA | 1.34B |
| Ramsay Générale de Santé SA | 5.01B |
Inventiva News
- 14 days ago - Inventiva provides a corporate update and reports its unaudited 2024 first-half financial results - GlobeNewsWire
- 2 months ago - Inventiva Reports Preliminary 2024 First-Half Financial Information¹ - GlobeNewsWire
- 2 months ago - Inventiva secures a new patent in Japan, expanding the IP protection of its lead product candidate lanifibranor - GlobeNewsWire
- 2 months ago - Half-Year Review of Inventiva's Liquidity Contract with Kepler Cheuvreux - GlobeNewsWire
- 3 months ago - Inventiva announces a €20.1 million issuance of royalty certificates - GlobeNewsWire
- 3 months ago - Inventiva: Solid MASH Program With Potential For Strategic Partnership Advancement - Seeking Alpha
- 3 months ago - Inventiva provides an update on its NATiV3 clinical program evaluating lanifibranor in patients with MASH/NASH and its financial position - GlobeNewsWire
- 3 months ago - Results of the votes of the Combined Shareholders' General Meeting of June 20, 2024 - GlobeNewsWire